Orexigen Therapeutics (OREX) Misses Q4 EPS by 21c

Orexigen Therapeutics (NASDAQ: OREX) reported Q4 EPS of $0.00, $0.21 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $22.95 million versus the consensus estimate of $49.65 million.

Contrave (naltrexone HCl / bupropion HCl extended release):

Orexigen's partner for North America, Takeda Pharmaceuticals, launched Contrave in the United States on October 20, 2014. U.S. net sales for the fourth quarter, recorded by Takeda, were $6.5 million, for which Orexigen earned $1.3 million in royalties. Gross sales for the quarter were $12.3 million.

Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia).

For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• Aon plc (AON) Misses Q1 EPS by 23c
• Centene (CNC) Tops Q1 EPS by 18c; Raises guidance